Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in …
Objectives In advanced non-small cell lung cancer (NSCLC), maintenance therapy has
emerged as a novel therapeutic reference for patients with non-progressive disease after …
emerged as a novel therapeutic reference for patients with non-progressive disease after …
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in …
M Sassier, AE Dugué, B Clarisse, P Lesueur, V Avrillon… - Lung Cancer, 2015 - infona.pl
In advanced non-small cell lung cancer (NSCLC), maintenance therapy has emerged as a
novel therapeutic reference for patients with non-progressive disease after platinum-based …
novel therapeutic reference for patients with non-progressive disease after platinum-based …
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in …
M Sassier, AE Dugué, B Clarisse, P Lesueur… - Lung …, 2015 - lungcancerjournal.info
Objectives In advanced non-small cell lung cancer (NSCLC), maintenance therapy has
emerged as a novel therapeutic reference for patients with non-progressive disease after …
emerged as a novel therapeutic reference for patients with non-progressive disease after …
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in …
M Sassier, AE Dugué, B Clarisse… - Lung Cancer …, 2015 - europepmc.org
In advanced non-small cell lung cancer (NSCLC), maintenance therapy has emerged as a
novel therapeutic reference for patients with non-progressive disease after platinum-based …
novel therapeutic reference for patients with non-progressive disease after platinum-based …
[PDF][PDF] Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung …
M Sassiera, AE Duguéa, B Clarissea, P Lesueura… - 2015 - academia.edu
abstract Objectives: In advanced non-small cell lung cancer (NSCLC), maintenance therapy
has emerged as a novel therapeutic reference for patients with non-progressive disease …
has emerged as a novel therapeutic reference for patients with non-progressive disease …
[引用][C] Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung …
M Sassier, AE Dugué, B Clarisse, P Lesueur, V Avrillon… - Lung Cancer, 2015 - cir.nii.ac.jp
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed)
discontinuation for toxicity to advanced non-small cell lung cancer in real world setting | CiNii …
discontinuation for toxicity to advanced non-small cell lung cancer in real world setting | CiNii …
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in …
M Sassier, AE Dugué, B Clarisse… - Lung cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Objectives In advanced non-small cell lung cancer (NSCLC), maintenance therapy has
emerged as a novel therapeutic reference for patients with non-progressive disease after …
emerged as a novel therapeutic reference for patients with non-progressive disease after …